Epilogue: Opioid Heterotopias

  • J. N. CampbellEmail author
  • Steven M. Rooney
Part of the SpringerBriefs in Molecular Science book series (BRIEFSMOLECULAR)


There was once a large hegemonic empire whose people possessed a great history. They had waged wars of conquest and defeated many enemies that threatened their way of life. Despite this, they verged on the declaration of a state of emergency. Over the past decade or so it was perceived that the addiction abuse rates of a certain drug had grown exponentially after a previous period of supposed tranquility when laws were passed banning the substance.


  1. 1.
    Travers M (1956) The life of Sir William Ramsay. Arnold, LondonGoogle Scholar
  2. 2.
    Pomeranz K (2001) The great divergence: China, Europe, and the making of the modern world economy. Princeton Univ Press, Princeton, NJGoogle Scholar
  3. 3.
    Acker CJ (2001) Creating the American Junkie: addiction research in the classic era of narcotic control. Johns Hopkins Univ Press, Baltimore, pp 135–139Google Scholar
  4. 4.
    Moynihan R, Cassels A (2006) Selling sickness: how the world’s biggest pharmaceutical companies are turning us all into patients. Nation Books, New York, pp 196–200Google Scholar
  5. 5.
    Daemmrich A (2005) Pharmacopolitics: drug regulation in the United States and Germany. University of North Carolina Press, Chapel Hill, pp 6, 9Google Scholar
  6. 6.
    Beauchamp T, Childress J (2012) Principles of biomedical ethics, 7th ed. Oxford University Press, Oxford, pp 94, 284Google Scholar
  7. 7.
    Glueck G (1987) Dr. Arthur Sackler dies at 73; Philanthropist and art patron. NYT May 27 Accessed 25 September 2017
  8. 8.
    Rosen W (2017) Miracle cure: the creation of antibiotics and the birth of modern medicine. Viking Press, New York, pp 227–228Google Scholar
  9. 9.
    Rooney S, Campbell JN (2017) How aspirin entered our medicine cabinet. Springer, Heidelberg, Springer Briefs in the History of Chemistry, p 42CrossRefGoogle Scholar
  10. 10.
    Greene JA, Watkins ES (eds) (2012) Prescribed: writing, filling, using, and abusing the prescription in Modern America. Johns Hopkins University Press, Baltimore, MDGoogle Scholar
  11. 11.
    Keefe P (2017) The family that built an empire of pain. New Yorker Oct 30 Accessed 31 Oct 2017
  12. 12.
    Glazek C (2017) The secretive family making billions from the Opioid Crisis. Oct 16 Accessed 31 Oct 2017
  13. 13.
    Acker CJ (2003) Take as directed: The dilemmas of regulating addictive analgesics and other psychoactive drugs. In: Meldrum M (ed) Opioids and pain relief: a historical perspective. IASP Press, Washington DC, pp 35–55Google Scholar
  14. 14.
    Goldacre B (2014) Bad pharma: how drug companies mislead doctors and harm patients. Farrar, Straus and Giroux, New York, pp 174, 313Google Scholar
  15. 15.
    Robbins L (2001) Louis Pasteur: and the hidden world of microbes. Oxford University Press, OxfordGoogle Scholar
  16. 16.
    Porter J, Jick H (1980) Addiction rare in patients treated with narcotics. N Engl J Med 302:123PubMedGoogle Scholar
  17. 17.
    Leung P, Macdonald EM, Stanbrook MB, Dhalla IA, Juurlink DN (2017) A 1980 letter on the risk of opioid addiction. N Engl J Med 376:2194–2195CrossRefPubMedGoogle Scholar
  18. 18.
    Burch D (2010) Taking the medicine: a short history of medicine’s beautiful idea, and our difficulty swallowing it. Random House UK, London, p 47Google Scholar
  19. 19.
    Abramson J (2008) Overdosed America: the broken promise of American medicine. Harper Perennial, New York, pp 102–103Google Scholar
  20. 20.
    Werth B (2014) The antidote: inside the world of new pharma. Simon & Schuster, New York, p 3Google Scholar

Copyright information

© The Author(s) 2018

Authors and Affiliations

  1. 1.Independent ScholarSpringUSA
  2. 2.Independent ScholarIrvingUSA

Personalised recommendations